|
|
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (74.1%), Europe (17%) and other (8.9%).
Number of employees : 11 800 people.
|
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | Innovative Medicines | 22,127 | 99.6% | 22,449 | 100.6% | +1.46% |
|
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | United States | 16,269 | 73.2% | 16,645 | 74.6% | +2.31% | | Europe | 4,006 | 18% | 3,811 | 17.1% | -4.87% | | Other International | 1,852 | 8.3% | 1,993 | 8.9% | +7.61% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
1,253,724,370 |
1,248,777,574 |
99.6% |
0 |
0.0% |
99.6% |
|
|
|
| Name | Equities | % | | Capital Research & Management Co. (Global Investors) | 125,356,882 |
10.00% | | The Vanguard Group, Inc. | 98,734,165 |
7.88% | | Putnam LLC | 83,388,336 |
6.65% | | Capital Research & Management Co. | 64,780,000 |
5.17% | | SSgA Funds Management, Inc. | 58,026,712 |
4.63% | | Capital Research & Management Co. (International Investors) | 57,143,147 |
4.56% | | Capital Research & Management Co. (World Investors) | 43,503,830 |
3.47% | | BlackRock Fund Advisors | 32,981,364 |
2.63% | | Geode Capital Management LLC | 19,665,435 |
1.57% | | Northern Trust Investments, Inc.(Investment Management) | 16,081,206 |
1.28% |
|
|
|
| Name | Equities | % | Valuation |
| Galapagos NV (GLPG) | 16,707,477 | 25.6% | 2,374,553,009 USD | | Allogene Therapeutics, Inc. (ALLO) | 7,486,689 | 5.37% | 282,323,042 USD | | Arcus Biosciences, Inc. (RCUS) | 8,163,029 | 12.6% | 139,914,317 USD | | Agenus Inc. (AGEN) | 11,111,111 | 6.06% | 44,444,444 USD | | HOOKIPA Pharma Inc. (HOOK) | 1,667,268 | 7.64% | 15,789,028 USD | | Sierra Oncology, Inc. (SRRA) | 348,017 | 3.35% | 3,713,341 USD |
|
|
|
|
- - Nasdaq Global Select Market - Nasdaq 100 / S&P 100, S&P 500, Stoxx Americas 100, Stoxx Global 200 |
|
|
|
|
| - Bloomberg Code : |
GILD:US |
| - Reuters Code : |
GILD.O |
| - Datastream Code : |
@GILD |
|
| Company contact information |
|
Gilead Sciences, Inc. 333 Lakeside Drive CA 94404 San Mateo, California Phone : +1 650 574 3000 Fax : +1 650 578 9264 Internet : http://www.gilead.com |
|
|
|
S&P, Nasdaq close higher as stimulus talks in spotlight |
Sector Bio Therapeutic Drugs
Connections : Gilead Sciences, Inc. |
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
